bluebird bio's GAAP loss for 9 months of 2023 was $123.3 million, down 2.5 times from $298.8 million in the prior year. Revenue increased 6-fold to $21.663 mln vs. $3.534 mln a year earlier.

Bluebird bio's GAAP loss for 2022 was $266.58 million, a three-fold decrease from $819.38 million in the previous year. Revenues fell 1.8% to $3.597 million from $3.662 million a year earlier.

Bluebird's GAAP loss for 9 months of 2022 was $298.81 million, down 2.2 times from $664.33 million in the previous year. Revenue increased 71.9% to $3.534 million from $2.056 million a year earlier.

Bluebird bio's GAAP loss for 6 months of 2022 was $222.29 million, down 50.3% from $447.51 million in the previous year. Revenue increased 3.3 times to $3.464 million from $1.037 million a year earlier.